Table 3.

KD5170 dose optimization in HCT-116 xenograft tumor bearing mice

Dose (mg/kg)RegimenT/CBodyweightMortality
8.4qd × 7107%−2%0/5
25qd × 759%−9.6%0/5
42qd × 711%−22%6/10
42qd × 524%−12%3/8
42qod × 744%−2%0/7
84qod × 717%−8.7%1/7
25qod × 1055%−1.5%0/8
50qod × 1035%−2.4%0/8
50qod × 1163%−2.6%0/10
75qod × 1135%−12.9%3/10
100qod × 1135%−15.7%8/10
  • NOTE: Compilation of a series of HCT-116 xenograft experiments comparing efficacy and tolerability of different dose regimens of KD5170. T/C, (treated final volume − treated initial volume) / (control final volume − control initial volume) × 100. Bodyweight at day after last dose relative to that at start. Mortality, number of animals that died or were sacrificed due to overt toxicity.